Photo by tannnpro from unsplash
The KRASG12C inhibitor sotorasib continues to impress in non-small cell lung cancer: In the phase II CodeBreak 100 trial, the agent elicited responses in more than a third of patients… Click to show full abstract
The KRASG12C inhibitor sotorasib continues to impress in non-small cell lung cancer: In the phase II CodeBreak 100 trial, the agent elicited responses in more than a third of patients and led to a median progression-free survival of almost 7 months. Based on these results, Amgen has filed for the drug's approval with the FDA and the European Medicines Agency.
Keywords:
closer approval;
approval;
edges closer;
sotorasib;
sotorasib edges
Journal Title: Cancer discovery
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!